Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: November 16, 2021
Event: Regulation FD Disclosure regarding the posting of an investor presentation to the company website.
Financial Metrics
This filing serves as a notice of an investor presentation and does not contain specific financial data. The text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes to financial performance or operations are detailed within the text of this specific 8-K filing. The document references an attached investor presentation (Exhibit 99.1) for detailed information.
Guidance, Outlook, and Risks
Management Commentary: The Company posted an investor presentation on November 16, 2021. The content of this presentation is not included in the filing text.
Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under the Securities Exchange Act of 1934 and is not subject to the liabilities of Section 18. It shall not be incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the content of the investor presentation attached as Exhibit 99.1 for actual financial guidance and operational updates.
- Note that the information in this 8-K is not incorporated by reference into other SEC filings.
- Confirm the trading symbols listed: Common Stock (BMY), 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).